The EU Court of Justice confirms the pay-for-delay infringement decision in the pharmaceutical sector (Lundbeck)

On 25 March 2021, the European Court of Justice (“ECJ”) dismissed all appeals against the 2016 rulings of the General Court which had upheld the European Commission’s (“Commission”) decision to fine Lundbeck and four generic pharmaceutical companies (Merck, Alpharma, Arrow and Ranbaxy) for concluding “pay-for-delay” patent settlement agreements in breach of Article 101 Treaty on the Functioning of the European Union (“TFEU”) (Cases C-586/16 P, Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission; C-588/16 P, Generics (UK) v Commis- sion; C-591/16 P, Lundbeck v Commission; C-601/16 P, Arrow Group and Arrow Generics v Commission; C-611/16 P, Xellia Pharmaceuticals

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Van Bael & Bellis (Brussels)

Citation

Steve Ross, The EU Court of Justice confirms the pay-for-delay infringement decision in the pharmaceutical sector (Lundbeck), 25 mars 2021, e-Competitions Due Process Research Program, Art. N° 100250

Visites 376

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues